Phase 2, multicenter, open‐label study of tigatuzumab (CS‐1008), a humanized monoclonal antibody targeting death receptor 5, in combination with gemcitabine in chemotherapy‐naive patients with unresectable or metastatic pancreatic cancer

Forero‐Torres, Andres; R. Infante, Jeffrey; Waterhouse, David; Wong, Lucas; M. Vickers, Selwyn; Arrowsmith, Edward; Ruth He, Aiwu; L. Hart, Lowell; Trent, David; L. Wade, James; Jin, Xiaoping; Wang, Qiang; Austin, TaShara; Rosen, Michael; A. Beckman, Robert; von Roemeling, Reinhard; Greenberg, Jonathan; N. Saleh, Mansoor

doi:10.1002/cam4.137

Public

Phase 2, multicenter, open‐label study of tigatuzumab (CS‐1008), a humanized monoclonal antibody targeting death receptor 5, in combination with gemcitabine in chemotherapy‐naive patients with unresectable or metastatic pancreatic cancer

Published in Cancer Medicine • Oct 25, 2013

Authors:

Andres Forero‐Torres

Jeffrey R. Infante

David Waterhouse

Abstract

Tigatuzumab is the humanized version of the agonistic murine monoclonal antibody TRA-8 that binds to the death receptor 5 and induces apoptosis of human cancer cell lines via the caspase cascade. The combination of tigatuzumab and gemcitabine inhibits tumor growth in murine pancreatic xenografts. Th...

Subject

Gemcitabine

Medicine

Pancreatic cancer

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!